SAN DIEGO--()--Illumina, Inc. (NASDAQ:ILMN) today unveiled its new HumanOmniExpress+ Custom BeadChip (OmniExpress+), an enhancement to the recently announced OmniExpress BeadChip that allows for the addition of up to 200,000 custom variants for a total of >900k variants per sample. OmniExpress+ leverages the proven iSelect custom genotyping infrastructure to provide researchers with unlimited flexibility in adding custom content for disease or pathway-specific markers, rare variants from the 1,000 Genomes Project, or panels for fine-mapping onto the industry’s most optimal set of SNPs.
“The OmniExpress+ continues Illumina’s tradition of supporting semi-custom products, joining the ranks of the 300-Duo+, 550-Quad+ and many others”
"The OmniExpress+ continues Illumina’s tradition of supporting semi-custom products, joining the ranks of the 300-Duo+, 550-Quad+ and many others,” said Jay Flatley, president and CEO of Illumina. “This addition to our family of third generation arrays leverages our many years of successful custom genotyping projects. The ability to add 3,000 to 200,000 custom variants to the standard OmniExpress provides tremendous flexibility to researchers while accessing the most optimal set of SNPs currently available for genome-wide association studies.”
The HumanOmniExpress+ Custom BeadChip is the most versatile custom genotyping product available, with industry-standard data quality ensured by the robust Infinium assay, flexible content design, and high throughput capabilities supported by a multisample BeadChip. Similar to researchers currently using iSelect, OmniExpress+ users will have access to Illumina’s assay design software for seamless content design, ensuring the best assay success rate in the industry without the need to pre-screen.
Together with the iScan System and an 8-sample array format, the OmniExpress+ enables the processing of more than 900 samples per week. Like OmniExpress, the foundation of the markers on the OmniExpress+ is a subset of the content powering Illumina's flagship GWAS product, the HumanOmni1-Quad, and includes an optimized set of SNPs chosen from all three phases of the International HapMap Project. Researchers starting with OmniExpress+ can take advantage of future supplemental Omni BeadChips containing new content derived from the 1,000 Genomes Project. As with all Infinium HD products, the OmniExpress BeadChip supports copy number variation (CNV) analyses for disease-association studies and is compatible with Illumina's automation solutions.
First customer shipments of the HumanOmniExpress+ Custom BeadChip are expected in the second quarter of 2010. For more information about the product, please visit our website at http://www.illumina.com/OmniExpress.
Illumina (www.illumina.com) is the leading developer, manufacturer, and marketer of integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping date for the OmniExpress+ Custom BeadChip. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.